Effects of antidepressant treatment on heart rate variability in major depression: a quantitative review
Source: DARE
Area: Evidence Medication Safety
CRD Summary: This review concluded that the use of tricyclic antidepressants in patients diagnosed with major depressive disorder lead to changes in heart rate variability that were associated with an increased risk of mortality. The authors' conclusions appeared to reflect the evidence but, given the methodological limitations, these conclusions should be interpreted with caution as they may not be reliable.
[Of the included studies, tricyclic antidepressants included amitriptyline, imipramine and doxepin. Selective serotonin reuptake inhibitor medications included fluvoxamine, paroxetine and fluoxetine. Other drugs included bupropion, mirtazapine, nefazodone and reboxetine. ]
CRD Commentary: This review addressed a clear question in t...
Somaxon Pharmaceuticals Announces Issuance Of Patent Relating To Pharmacokinetics (Food Effect) Of Silenor
Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. patent no. 7,915,307, entitled Methods of Improving the Pharmacokinetics of Doxepin. This patent generally relates to dosing Silenor® (doxepin) at least three hours after a meal to promote faster onset of action and reduce the potential for next-day residual sedation. This patent will expire no earlier than July 2027, and Somaxon has submitted to the U.S... (Source: Health News from Medical News Today)
